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Intake of dairy products 
and associations with major 
atherosclerotic cardiovascular 
diseases: a systematic review 
and meta‑analysis of cohort studies
Marianne Uhre Jakobsen 1*, Ellen Trolle 2, Malene Outzen 1, Heddie Mejborn 2, 
Manja G. Grønberg 3, Christian Bøge Lyndgaard 3, Anders Stockmarr 3, Stine K. Venø 
4 & Anette Bysted 5
Specific types of dairy products may be differentially associated with atherosclerotic cardiovascular 
disease (CVD). We conducted a systematic review and meta‑analysis of cohort studies to summarize 
findings on the associations between total dairy product intake and intake of dairy product subgroups 
and the risk of major atherosclerotic CVDs in the general adult population. Our protocol was registered 
in PROSPERO (CRD42019125455). PubMed and Embase were systematically searched through 15 
August 2019. For high versus low intake and dose–response meta‑analysis, random‑effects modelling 
was used to calculate summary risk ratios (RR). There were 13 cohort studies included for coronary 
heart disease (CHD), 7 for ischemic stroke and none for peripheral artery disease. High‑fat milk was 
positively associated with CHD (RR 1.08 (95% confidence interval 1.00–1.16) per 200 g higher intake/
day) and cheese was inversely associated with CHD (RR 0.96 (95% confidence interval 0.93–0.98) per 
20 g higher intake/day). Heterogeneity, however, was observed in high versus low meta‑analyses. Milk 
was inversely associated with ischemic stroke in high versus low meta‑analysis only. In conclusion, this 
systematic review indicates a positive association of high‑fat milk and an inverse association of cheese 
with CHD risk. The findings should be interpreted in the context of the observed heterogeneity.
Elevated low-density lipoprotein (LDL)-cholesterol is an important risk factor of atherosclerosis (a disease of 
the large arteries), which is the primary cause of atherosclerotic cardiovascular diseases (CVDs)1. Nutrient trials 
have shown that intake of saturated fatty acids increases serum LDL-cholesterol relative to intake of unsaturated 
fatty acids and  carbohydrates2. As whole-fat dairy products have a high saturated fat content, food-based dietary 
guidelines recommend consumption of low-fat dairy products in place of high-fat dairy  products3. However, the 
health effects of saturated fat varies depending on the specific fatty acid and possibly by the specific food  source4,5.
The role of dairy foods in CVD prevention has been reviewed and  summarized6–9. Because dairy is a hetero-
geneous food group of solid, semi solid and liquid fermented or non-fermented products, differing in nutrients 
and probiotics found in fermented dairy products, the focus has been on the intake of specific types of dairy 
products in relation to CVD development rather than on total intake of dairy products. In a systematic review 
and meta-analysis from 2017 by Guo et al.9 associations between intake of milk, yogurt and cheese and risk of 
coronary heart disease (CHD) were summarized. No associations between intake of any of the investigated dairy 
product subgroups and CHD were observed. In a systematic review and meta-analysis from 2016 by de Goede 
et al.6 associations between intake of milk, yogurt, cheese and butter and risk of stroke were summarized. A 
higher intake of milk was found associated with a lower risk of stroke, and a higher intake of high-fat milk was 
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found to be associated with a higher risk of stroke. No associations between the intake of low-fat milk, yogurt, 
cheese or butter and stroke were observed. In subgroup analyses by stroke type (ischemic and hemorrhagic), 
no associations were observed with milk intake. Associations between stroke type and intake of low-fat milk or 
high-fat milk were not considered; nor were associations with other dairy product subgroups.
We conducted a systematic review and meta-analysis of cohort studies to summarize the findings on the 
associations between total intake of dairy products and intake of dairy product subgroups (milk, yogurt, cheese 
and butter) and the risk of major atherosclerotic CVDs (total (the sum of fatal and nonfatal) CHD, total ischemic 
stroke and peripheral artery disease) in the general adult population. Data synthesis was also differentiated 
according to the fat content of the dairy product subgroups. The focus of this systematic review is on athero-
sclerotic CVDs because dairy products may play an important role in prevention of atherosclerotic CVDs. We 
included only studies considering total CHD and total ischemic stroke as outcomes. Studies on total CHD and 
total ischemic stroke may be seen as studies on etiology of CHD and ischemic stroke, respectively, whereas stud-
ies on only fatal outcomes may be seen as studies exploring combined etiology and prognosis. The associations 
between dairy and major atherosclerotic CVDs were investigated using high versus low intake and dose–response 
(linear and non-linear) meta-analysis.
Methods
Protocol and registration. This systematic review and meta-analysis was planned and conducted accord-
ing to the preferred reporting items for systematic reviews and meta-analyses (PRISMA)10,11. The systematic 
review protocol, including review question, search strategy, eligibility criteria (participants, exposure, com-
parator, outcome and study design (PECOS) items) and risk of bias assessment, was registered in PROSPERO 
International Prospective Register of Systematic Reviews (http://www.crd.york.ac.uk/PROSP ERO, identifier 
CRD42019125455) ahead of conducting the review. The PRISMA checklist has been submitted to the journal as 
an attachment to this article (see Supplementary Table S1 online).
Eligibility criteria. Participants: Participants recruited from the general adult population.
Exposure: Considering at least one of the exposures total intake of dairy products, intake of low-fat dairy 
products, intake of high-fat dairy products, intake of milk, intake of low-fat milk (fat content lower than whole-fat 
milk), intake of high-fat milk (fat content equalling whole-fat milk), intake of yogurt/other soured milk products 
(referred to hereinafter as yogurt), intake of low-fat yogurt/other soured milk products (fat content lower than 
whole-fat yogurt/other soured milk products, referred to hereinafter as low-fat yogurt), intake of high-fat yogurt/
other soured milk products (fat content equalling whole-fat yogurt/other soured milk products, referred to here-
inafter as high-fat yogurt), intake of cheese, intake of low-fat cheese, intake of high-fat cheese and intake of butter.
Comparator: When the exposure is total intake of dairy products, the comparator is a lower intake of total 
intake of dairy products and when the exposure is intake of a dairy product subgroup, the comparator is a lower 
intake of that particular dairy product subgroup.
Outcome: Considering at least one of the outcomes total CHD, total ischemic stroke and peripheral artery 
disease.
Study design: Cohort study that provides evidence about associations between exposures and incidence of 
hard outcomes.
Only published articles were considered. There were no restrictions to language.
Search. Studies were identified by searching the bibliographic databases PubMed and Embase (through 15 
August 2019). The search included only terms related to exposures and outcomes. The full literature search strat-
egy for PubMed is shown in Supplementary Methods online. Additionally, we checked the reference lists of the 
included studies. Previous reviews and meta-analyses were also used as an information source.
Study selection. An eligibility assessment was performed independently in a standardised manner by two 
reviewers (M.U.J. and M.O. or M.U.J. and E.T.). Titles and/or abstracts of records identified through the search 
were screened against the eligibility criteria. The full text of articles that appeared to meet the study eligibility 
criteria, or where there was any uncertainty about eligibility, was retrieved and assessed for eligibility. Any disa-
greement between the two reviewers over the eligibility assessment of a particular study was resolved by discus-
sion. The PRISMA flow  diagram11 was used to summarize the study selection processes.
Data collection process and data items. A data extraction sheet (developed a priori by the reviewers 
and pilot-tested) was used to extract data from the included studies. One reviewer (M.U.J.) extracted the follow-
ing data items from the studies and a second reviewer (M.O., E.T., M.G.G., C.B.L. or S.K.V.) checked the extracted 
data: First author’s last name, publication year, cohort name, study origin, recruitment year/period, gender, age 
at entry, sample size, exclusion criteria, exposure and exposure definition, exposure frequency and quantity 
(M.O.); method for collecting information on exposure (E.T.); outcome, method for ascertainment of outcome 
(S.K.V.); length of follow-up, lost to follow-up, adjustment variables; total number of events (M.O.); number of 
events per exposure level, number of participants or person-years per exposure level (M.G.G. or C.B.L.); point 
risk estimates for associations and their confidence limits, funding sources (M.O.). When risk estimates from 
more than one multivariable analysis were reported, we extracted data from the analysis adjusting for the largest 
number of confounders. Moreover, if risk estimates from specified substitution analyses were reported, only risk 
estimates for substitutions between dairy products were extracted. Any disagreement between the two reviewers 
over the extracted data of a particular study was resolved by discussion. We contacted (by e-mail) 12  authors12–23 
of the included studies for further information on study methods (exposure definition, quantitative amount) and 
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results (number of events per exposure category, number of participants or person-years per exposure category). 
In case a study was published more than once, we included the most comprehensive study in terms of exposures 
considered or sample size if exposure was the same.
Risk of bias in individual studies. Risk of bias judgements of the included studies were based on the New-
castle–Ottawa scale (NOS)  tool24. Two reviewers (M.U.J. and E.T. or M.U.J. and S.K.V.) independently assessed 
the internal validity of the included studies by assessing risk of selection bias, information bias and confounding. 
Any disagreement between the two reviewers over the risk of bias judgements (“low risk” of bias, “high risk” 
of bias, “unclear risk” of bias) of a particular study was resolved by discussion. A cross-tabulation of study by 
quality item was used to present the risk of bias judgements. A study was classified as being at low risk of bias in 
general only if ≤ 2 of the 8 items established a “high risk” or “unclear risk” of bias.
Data processing and statistical analysis. A summary table was used to present characteristics of the 
included studies. The measure of associations in the included studies were hazard ratios (the most common 
measure) and odds ratios, but both measures were treated as risk ratios (RRs) in the meta-analysis25. Standard 
error estimates for point risk estimates were recovered from confidence limits. Studies for which information 
on point risk estimates and confidence limits was not reported were left out. Where results were reported in all 
participants and in men and women separately, we used results in men and results in women.
When intake by exposure category was provided as a point estimate, we used this for the corresponding risk 
estimate. Where a range of intake was provided, we calculated the midpoint. Where a lower intake range was 
open-ended, we calculated the midpoint between zero and the given lower boundary; and when an upper intake 
range was open-ended, we assumed that its width was the same as the adjacent category. In case this category was 
a point estimate, then the nearest intake range was used. For studies where intake was provided only as serving 
size (and where the quantitative amount was not specified), we used conversion standards (see Supplementary 
Table S2 online).
Quantitative data synthesis was conducted where studies had used similar exposure with similar outcome. 
For high versus low intake and dose–response meta-analysis, a random-effects model was used to calculate sum-
mary RR estimates and corresponding 95% confidence intervals (CIs), which incorporated both within- and 
between-study  variability26. The inverse variance method was used for weighting the studies and the DerSimonian 
& Laird estimator was used to estimate the between study  variance26. In high versus low intake meta-analysis, 
the reference category was the lowest intake category (for most studies) or no intake as reported in the included 
studies. Linear dose–response meta-analysis was carried out as a two-stage procedure. In the first stage, a slope 
(trend) for each study was calculated, and in the second stage, the study-specific slope estimates were combined 
using the random-effects  model26. For studies where a linear dose–response trend was reported, we used this for 
the analysis. For studies not reporting a linear dose–response trend, we calculated study-specific linear trends 
and corresponding CIs from the natural logs of the point risk estimates of the exposure categories and their 
confidence limits. The covariance between the log risk estimates within each study was approximated using the 
method of Greenland &  Longnecker27. This method requires information on the distribution of cases and the 
number of participants or person-years for each exposure category. Thus, studies for which this information was 
not provided were left out. However, in case the distribution of participants was not provided in studies where the 
exposure was defined in quantiles, the distribution was calculated by dividing the total number of participants 
by the number of quantiles. For studies with only two exposure categories, the covariance matrix between the 
log risk estimates only consisted of the variance of the log risk estimate for the non-referent exposure category. 
Thus, no covariance matrix had to be approximated by the method of Greenland &  Longnecker27, resulting in the 
exception that when only one non-referent intake category was present, the study was not left out even though 
the number of participants and the number of cases for the exposure categories were not provided. For linear 
dose–response meta-analysis, the combined trend was reported as risk per higher intake in grams per day as 
follows: for milk 200 g/day, yogurt 100 g/day, cheese 20 g/day, butter 6 g/day. For linear dose–response meta-
analysis of substitutions between dairy product subgroups, however, the combined trend was reported as risk per 
1 serving/day substituted. Studies were left out when information on quantitative amount of exposure categories 
was not provided. Non-linear dose–response meta-analysis was also carried out as a two-stage procedure. In 
the first stage, a restricted cubic spline model using three knots at 10%, 50% and 90% of the total distribution of 
the reported intake was applied for each study with at least three exposure categories, and in the second stage, 
the study-specific estimates were combined using the random-effects  model26,28. The method of Greenland & 
 Longnecker27 was also used for this analysis. A Wald test was used to test whether the non-linear model could 
be reduced to a linear model.
We used Cochran’s Q test and calculated the I2 statistic to explore statistical heterogeneity between  studies29. 
Furthermore, in order to identify potential sources of heterogeneity, we performed pre-specified subgroup meta-
analysis by study characteristics (gender and continent (Asia, Europe and North America)). The random-effects 
model was used within each subgroup, whereas a fixed-effects model was used across subgroups. The qualitative 
data synthesis revealed that the age of the study population and the length of follow-up time were rather homog-
enous across studies, thus, pre-specified subgroup analyses by age at entry (< 50 years, ≥ 50 years) and follow-up 
time (< 10 years, ≥ 10 years) were not undertaken.
We performed sensitivity analyses excluding studies where > 2 of the quality items in the risk of bias assess-
ment established a “high risk” or “unclear risk” of bias. Furthermore, comparative fixed-effects models were per-
formed as a basis for providing evidence for the necessity of random-effects modelling. Potential publication bias 
(risk of bias across studies) was assessed both formally with Egger’s test, if at least three studies were  available30, 
and visually using funnel plots of the study-specific point risk estimates by the inverse of their standard errors.
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Statistical analyses were performed using R, version 3.6.131, with packages  dmetar32,  meta33 and  dosresmeta34. 
Two-sided P-values < 0.05 were considered statistically significant. P-values < 0.1 were given with one significant 
digit.
We used the  NutriGrade35 scoring system to evaluate the quality of evidence of the linear dose–response 
meta-analyses (i.e. meta-evidence) for each dairy product subgroup. The NutriGrade scoring system (maximum 
of 10 points), which has shown good agreement and reliability, includes the following eight items: risk of bias 
assessment of cohort studies (maximum of 2 points), precision (maximum of 1 point), heterogeneity (maximum 
of 1 point), directness (maximum of 1 point), publication bias (maximum of 1 point), funding bias (maximum of 
1 point), effect size (maximum of 2 points) and dose–response (maximum of 1 point). On the basis of this scoring 
system, four categories to judge the meta-evidence are recommended: high meta-evidence (≥ 8 points), moderate 
meta-evidence (6–7.99 points), low meta-evidence (4–5.99 points) and very low meta-evidence (0–3.99 points).
Associations for total intake of dairy products are not readily comparable between studies because total 
intake of dairy products represents variable products with variable serving sizes. Therefore, data synthesis was 
constrained to qualitative data synthesis, without a summary RR estimate.
Results
Out of the 7,768 records identified through database searching and other sources, 88 full-text articles were 
assessed for eligibility and 33 studies met our eligibility  criteria12–23,36–56 (see Supplementary Fig. S1 online). 
The entire list of the 55 full-text articles excluded, with reasons can be found as Supplementary Table S3 online. 
Among the studies that met our eligibility criteria, three  studies46,49,54 were subsequently excluded due to dupli-
cate publications (Nurses’ Health  Study12,54,  Caerphilly13,49, Health Professionals Follow-up  Study46,55). In three 
other studies, there was overlap between the study populations (Malmö Diet and Cancer cohort (one of the 
Swedish contributions to the European Prospective Investigation Into Cancer and Nutrition (EPIC) cohort)16, 
EPIC-NL cohort (the Dutch contribution to the EPIC cohort)52,  EPIC21) and the exposures considered. The 
three studies were retained but only the results on the common exposures (milk, yogurt, cheese) from the EPIC 
 cohort21 were included in the data synthesis. From the Malmö Diet and Cancer  cohort16, the results on total 
dairy and butter were included in the data synthesis, and from the EPIC-NL  cohort52, the results on total dairy, 
low-fat dairy and high-fat dairy were included in the data synthesis due to the different exposures than in the 
EPIC  cohort21. Thus, 30 studies were included in the qualitative data  synthesis12–23,36–45,47,48,50–53,55,56 (20 studies 
for  CHD12,13,16–22,37–40,45,48,50–53,56 and 12 for ischemic  stroke13–15,23,36,40–44,47,55). Included in the meta-analysis were 
18  studies12–22,37,38,40,42–45 (13 studies for  CHD12,13,16–22,37 38,40,45 and 7 for ischemic  stroke13–15,40,42–44). No studies 
on peripheral artery disease were identified.
Table 1 shows the characteristics of the 20 studies on  CHD12,13,16–22,37–40,45,48,50–53,56. Among the 20 studies, 5 
presented gender-specific  results17,20,21,50,53, 3 comprised only  men13,45,56 and 3 comprised only  women12,18,40. A 
single study was from  Asia22, 13 from  Europe13,16,18–21,37–39,45,50,52,53 and 5 from North  America12,17,40,48,56. A single 
study comprised 21 countries in 5  continents51. The age at entry ranged from 38 to 72 years and the length of 
follow-up time from 5 to 22 years. All studies except for two of  them22,51 were classified as being at low risk of 
bias (see Supplementary Table S4 online). 
Table 2 shows the characteristics of the 12 studies on ischemic  stroke13–15, 23, 36, 40–44, 47, 55. Among the 12 stud-
ies, 1 study presented gender-specific  results55, 3 comprised only  men13, 15, 23 and 3 comprised only  women14, 36, 
40. One study was from  Asia41, five from  Europe13, 15, 42–44 and six from North  America14, 23, 36, 40, 47, 55. The age at 
entry ranged from 46 to 65 years and the length of follow-up time from 8 to 23 years. All studies except for three 
of  them23, 41, 43 were classified as being at low risk of bias (see Supplementary Table S4 online).
Supplementary Table S5 online shows the definition of dairy products as described in the studies, and Supple-
mentary Table S6 online comprises an overview of which of the studies contributed to each of the meta-analyses. 
Supplementary Table S7 online shows the funding sources of the studies.
Total dairy. Overall, the studies indicated no association between total intake of dairy, intake of low-fat dairy 
or intake of high-fat dairy and risk of CHD or ischemic stroke (see Supplementary Fig. S2-S4 online).
Milk. For milk, 6 studies with 619,460 participants and 16,478 cases were included in the high versus low 
intake meta-analysis for CHD (overall intake range: 0–710 g/d). Comparing the highest with the lowest cat-
egory of milk intake, no association was observed for CHD (RR 1.02 (95% CI 0.92–1.13); I2 = 67%; Pheterogenity 
(Phet) < 0.01) (see Supplementary Fig. S5 online). Comparing the highest with the lowest category of low-fat milk 
intake, no association with CHD was observed (RR 1.05 (95% CI 0.92–1.20); I2 = 59%; Phet = 0.03; n studies = 5), 
whereas comparing the highest with the lowest category of high-fat milk intake, a higher risk of CHD was 
observed (RR 1.16 (95% CI 1.01–1.33); I2 = 53%; Phet = 0.04; n studies = 6) (see Supplementary Fig. S5 online). The 
observed heterogeneity between studies was not explained by pre-specified subgroup analyses (see Supplemen-
tary Table S8 online). In linear dose–response meta-analysis, no associations were observed between milk intake 
or low-fat milk intake and CHD (Fig. 1). However, each additional daily 200 g of high-fat milk was associated 
with an 8% higher risk of CHD (RR 1.08 (95% CI 1.00–1.16); I2 = 0%; Phet = 0.94; n studies = 4) (Fig. 1). Supple-
mentary Table S9 online shows subgroup dose–response meta-analysis by study characteristics. No evidence of 
non-linear dose–response associations was observed (data not shown).
Three studies with 163,128 participants and 3,691 cases were included in the high versus low intake meta-
analysis for milk and ischemic stroke (overall intake range: 0–710 g/day). Comparing the highest with the low-
est category of milk intake, a lower risk of ischemic stroke was observed (RR 0.88 (95% CI 0.79–0.98); I2 = 0%; 
Phet = 0.52) (see Supplementary Fig. S5 online). In linear dose–response meta-analysis, no association between 
milk intake and ischemic stroke was observed (Fig. 1). Supplementary Tables S8 and S9 online show subgroup 
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meta-analysis by study characteristics. No evidence of a non-linear dose–response association was observed 
(data not shown).
Yogurt. For yogurt, 6 studies with 552,342 participants and 14,226 cases were included in the high versus 
low intake meta-analysis for CHD (overall intake range: 0–440 g/day). Comparing the highest with the low-
est category of yogurt intake, no association with CHD was observed (RR 0.99 (95% CI 0.91–1.08); I2 = 49%; 
Phet = 0.06) (see Supplementary Fig. S6 online). In pre-specified subgroup analysis by continent, however, hetero-
geneity between continents was observed (P < 0.05) but no association between yogurt and CHD was observed 
in studies from Europe (RR 0.96 (95% CI 0.89–1.04); I2 = 42%; Phet = 0.12; n studies = 5) or in studies from North 
America (RR 1.25 (95% CI 0.97–1.61); I2 = 0%; Phet = 0.71; n studies = 1) (see Supplementary Table S10 online). 
No association between low-fat or high-fat yogurt and CHD was observed (see Supplementary Fig. S6 online). 
In linear dose–response meta-analysis, no association between yogurt and CHD was observed (RR 0.98 (95% 
CI 0.93–1.03) per 100 g higher intake per day; I2 = 42%; Phet = 0.11; n studies = 5) (Fig. 2). However, heterogeneity 
between continents was observed (P < 0.05) but no association between yogurt and CHD was observed in studies 
from Europe (RR 0.97 (95% CI 0.93–1.01) per 100 g higher intake per day; I2 = 35%; Phet = 0.19; n studies = 4) or 
in studies from North America (1.20 (95% CI 0.98–1.48) per 100 g higher intake per day; I2 = 0%; Phet = 0.71; n 
studies = 1) (see Supplementary Table S11 online). No evidence of a non-linear dose–response association was 
observed (data not shown).
Three studies with 187,281 participants and 6,208 cases were included in the high versus low intake meta-
analysis for yogurt and ischemic stroke (overall intake range: 0–400 g/day). Comparing the highest with the 
lowest category of yogurt intake, no association for ischemic stroke was observed (see Supplementary Fig. S6 
online). Supplementary Table S10 online shows subgroup high versus low intake meta-analysis by study charac-
teristics. Also in linear dose–response meta-analysis, no association between yogurt intake and ischemic stroke 
was observed (Fig. 2).
Cheese. For cheese, 7 studies with 554,323 participants and 14,698 cases were included in the high ver-
sus low intake meta-analysis for CHD (overall intake range: 0–120  g/day). Comparing the highest with the 
lowest category of cheese intake, a lower risk of CHD was observed (RR 0.91 (95% CI 0.84–0.99); I2 = 37%; 
Phet = 0.12) (see Supplementary Fig. S7 online). In pre-specified subgroup analysis by gender, however, hetero-
geneity between genders was observed (P = 0.03) (see Supplementary Table S12 online). In studies among men, 
comparing the highest with the lowest category of cheese intake, no association with CHD was observed (RR 
1.03 (95% CI 0.93–1.13); I2 = 0%; Phet = 0.74; n studies = 3). In studies among women, comparing the highest with 
the lowest category of cheese intake, a lower risk of CHD was observed (RR 0.82 (95% CI 0.69–0.97); I2 = 33%; 
Phet = 0.23; n studies = 3). No association between low-fat or high-fat cheese intake and CHD was observed but 
heterogeneity for low-fat cheese intake was observed (see Supplementary Fig. S7 online). The observed hetero-
geneity between studies was not explained by subgroup analyses (see Supplementary Table S12 online). In linear 
dose–response meta-analysis, each additional daily 20 g of cheese was associated with a 4% lower risk of CHD 
(RR 0.96 (95% CI 0.93–0.98); I2 = 3%; Phet = 0.41; n studies = 6) (Fig. 3) and no heterogeneity between genders was 
observed (P = 0.55) (see Supplementary Table S13 online). In studies among men, the summary RR estimate for 
cheese intake of 20 g/day was 0.96 (95% CI 0.92–1.00) and in studies among women, the summary RR estimate 
for cheese intake of 20 g/day was 0.94 (95% CI 0.90–0.98). No association between low-fat cheese intake and 
CHD was observed but heterogeneity was observed (Fig. 3). The observed heterogeneity between studies was 
not explained by subgroup analyses (see Supplementary Table S13 online). No evidence of a non-linear dose–
response association was observed (data not shown).
Three studies with 187,281 participants and 6,208 cases were included in the high versus low intake meta-anal-
ysis for cheese and ischemic stroke (overall intake range: 0–400 g/day). Comparing the highest with the lowest 
category of cheese intake, no association with ischemic stroke was observed (see Supplementary Fig. S7 online). 
Supplementary Table S12 online shows subgroup high versus low intake meta-analysis by study characteristics. 
Also in linear dose–response meta-analysis, no association between cheese intake and ischemic stroke was 
observed but heterogeneity was observed (Fig. 3). The observed heterogeneity between studies was not explained 
by subgroup analyses (see Supplementary Table S13 online). No evidence of a non-linear dose–response associa-
tion was observed (data not shown).
Butter. For butter, 4 studies with 128,757 participants and 6,562 cases were included in the high versus low 
intake meta-analysis for CHD (overall intake range: 0–63 g/day). Comparing the highest with the lowest cat-
egory of butter intake, no association was observed for CHD (see Supplementary Fig. S8 online). Also in linear 
dose–response meta-analysis, no association between butter intake and CHD was observed (Fig. 4). Supplemen-
tary Tables S14 and S15 online show subgroup meta-analysis by study characteristics.
In linear dose–response meta-analysis, no association between butter intake and ischemic stroke was observed 
(Fig. 4).
Substitutions between dairy product subgroups. In linear dose–response meta-analysis, no associa-
tions between substitutions among dairy product subgroups (low-fat milk, high-fat milk, low-fat yogurt, high-
fat yogurt, cheese and butter) and risk of ischemic stroke were observed (Fig. 5).
Sensitivity analyses. One  study22, investigating high-fat milk intake and risk of CHD, was excluded in low 
risk of bias sensitivity analysis. The reanalyses produced small changes in the summary RR estimates and cor-
responding 95% CIs (see Supplementary Fig. S9 online). Using a fixed-effects model to calculate summary RR 
14
Vol:.(1234567890)











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Scientific Reports |         (2021) 11:1303  | https://doi.org/10.1038/s41598-020-79708-x
www.nature.com/scientificreports/
estimates and corresponding 95% CIs produced narrower CIs, and eight of the summary RR estimates became 
statistically significant (see Supplementary Table S16 online). Among these analyses, heterogeneity was observed 
in four analyses; thus, the narrower CIs from the fixed-effects model were not considered reliable. In four other 
analyses, no heterogeneity was observed. In these analyses, except for one, the fixed-effects model produced bor-
derline statistical significance with CIs including 0.99. The exception was the linear dose–response meta-analysis 
of substitution of low-fat yogurt for high-fat yogurt where the fixed-effects model produced statistical signifi-
cance with a CI of 1.03–1.50 while Cochran’s Q-test for heterogeneity was borderline statistically significant with 
P = 0.08 (I2 = 67%). In that case, we deem the analysis inconclusive. There was no evidence of publication bias 
Figure 1.  Linear dose–response meta-analysis. Summary RR of CHD (panel a) and ischemic stroke (panel 
b) per 200 g higher intake of milk/day. P = 0.12 for the association between milk and CHD. P = 0.04 for the 
association between high-fat milk and CHD. CHD coronary heart disease; CI confidence interval; M males; RR 
risk ratio; W women.
20
Vol:.(1234567890)
Scientific Reports |         (2021) 11:1303  | https://doi.org/10.1038/s41598-020-79708-x
www.nature.com/scientificreports/
with the exception of high versus low intake meta-analysis of yogurt and risk of CHD (Egger’s test: P < 0.01). Vis-
ual inspection of funnel plots suggested moderate small study effects towards the null for yogurt intake and risk 
of CHD in both high versus low intake and dose–response meta-analysis (see Supplementary Fig. S10 online).
Quality of meta‑evidence. Table 3 provides an overview of the findings from linear dose–response meta-
analysis on dairy product subgroups and risk of CHD, and NutriGrade meta-evidence grading. The grading was 
rated moderate for high-fat milk and cheese, and low for milk, low-fat milk, yogurt, low-fat cheese and butter.
Table 4 provides an overview of the findings from linear dose–response meta-analysis on dairy product sub-
groups and risk of ischemic stroke, and NutriGrade meta-evidence grading. The grading was rated low for milk, 
yogurt, cheese and butter, and very low for all substitutions between dairy product subgroups.
Discussion
Intake of dairy product subgroups and associations with major atherosclerotic CVDs in the general adult popula-
tion was investigated in this systematic review and meta-analysis of cohort studies through comparison of the 
highest with the lowest intake categories and dose–response (linear and non-linear) analyses. Intake of high-
fat milk was positively associated with the risk of CHD, with heterogeneity present in high versus low intake 
meta-analysis, which could not be explained by pre-specified subgroup analyses. However, no heterogeneity 
was observed in linear dose–response meta-analysis. For total intake of milk and intake of low-fat milk, no 
associations were observed. Intake of cheese was inversely associated with the risk of CHD, with heterogeneity 
between genders present in high versus low intake meta-analysis. In studies among women, high cheese intake 
compared with low cheese intake was associated with lower CHD risk but not in studies among men. However, 
no heterogeneity between genders was observed in linear dose–response meta-analysis. For intake of low-fat 
cheese, yogurt and butter, no associations with CHD were observed. Milk intake was inversely associated with 
the risk of ischemic stroke in high versus low intake meta-analysis but not in dose–response meta-analysis. For 
intake of cheese, yogurt and butter no associations with ischemic stroke were observed. The NutriGrade tool for 
evaluating the quality of meta-evidence suggested a moderate confidence in the summary RR estimates for the 
associations between high-fat milk and cheese and CHD; further research could add evidence on the confidence 
and may change the effect estimates. For all other summary RR estimates, the tool suggested a low confidence 
in the effect estimates (further research will provide important evidence on the confidence and likely change 
the estimates) or a very low confidence in the effect estimates (meta-evidence is very limited and uncertain).
For total intake of dairy, intake of low-fat dairy and intake of high-fat dairy, data synthesis was constrained 
to qualitative data synthesis without a summary RR estimate. Overall, these studies indicated no association 
between total intake of dairy, intake of low-fat dairy or intake of high-fat dairy and CHD or ischemic stroke.
Figure 2.  Linear dose–response meta-analysis. Summary RR of CHD (panel a) and ischemic stroke (panel b) 
per 100 g higher intake of yogurt/day. Yogurt defined as yogurt/other soured milk products. CHD coronary 
heart disease; CI confidence interval; M males; RR risk ratio; W women.
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The strengths of our systematic review are the direct evidence, the focus on atherosclerotic CVDs and the 
inclusion of only studies considering total CHD and total ischemic stroke as outcomes. Previous meta-analyses 
on dairy intake and CHD and stroke combined results from studies on total and fatal  outcomes6–9. Moreover, 
our data synthesis was also differentiated according to the fat content of the dairy product subgroups. Whole-fat 
dairy products have a high saturated fat content and nutrient trials have shown that intake of saturated fatty acids 
increases serum LDL-cholesterol relative to intake of unsaturated fatty acids and  carbohydrates2. Elevated LDL-
cholesterol is an important risk factor of atherosclerosis, which is the primary cause of atherosclerotic  CVDs1. 
In addition, we carefully considered dairy product subgroups and contacted authors of the included studies for 
further information on exposure definition. The quality of a systematic review and meta-analysis depends on 
the quality of the included studies. The  NOS24 is a commonly used tool for quality ranking of cohort studies. 
However, the NOS tool does not focus on internal validity alone as also was emphasized by  Stang57. We employed 
a modified instrument based on the NOS tool. We assessed the quality of the included studies by assessing eight 
items concerning the internal validity, categorized into three domains (selection bias, information bias and com-
parability) similar to the domains in the NOS tool. Studies were classified as being at low risk of bias in general if 
only ≤ 2 of the 8 quality items established a “high risk” or “unclear risk” of bias. In sensitivity analyses, we repeated 
the meta-analyses including only studies deemed low risk of bias. The reanalyses produced small changes in the 
CIs; thus, the confidence limits appeared to be insensitive to judgements about study quality. We did not include 
selective reporting of outcome and analyses in our assessment of the quality of the cohort studies because most 
cohort studies are not registered before being conducted. We performed comparative fixed-effects modelling to 
evaluate the robustness of the results, which provided evidence for the necessity of random-effects modelling. 
Figure 3.  Linear dose–response meta-analysis. Summary RR of CHD (panel a) and ischemic stroke (panel b) 
per 20 g higher intake of cheese/day. P < 0.05 for heterogeneity for the association between cheese and ischemic 
stroke. CHD coronary heart disease; CI confidence interval; M males; RR risk ratio; W women.
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Finally, we also evaluated the meta-evidence for each dairy subgroup using a comprehensive approach; namely 
the  NutriGrade35 scoring system.
Limitations of our systematic review are that the number of included studies was low, limiting the possibil-
ity to detect heterogeneity for several exposures and to identify potential sources of heterogeneity in subgroup 
analyses by study characteristics. The qualitative data synthesis revealed that the age at entry of the study popu-
lations (≥ 50 years in all studies, except for 2 studies) and length of follow-up (≥ 10 years, except for 1 study) 
were homogenous across studies but sources of bias were present and these biases varied across the studies as 
demonstrated in our risk of bias judgement. For example, socioeconomic status is a risk factor of  CVD58, 59 
and low-fat dairy products are more likely to be consumed by groups of higher socioeconomic  status60. How-
ever, most studies adjusted for education and other relevant risk factors of atherosclerotic CVD such as gender 
(as appropriate), age, total energy intake, smoking, physical activity, alcohol consumption, body mass index 
and comorbidity. We observed no evidence of publication bias with the exception of high versus low intake 
meta-analysis of yogurt and risk of CHD (Egger’s test: P < 0.01). However, large P-values do not indicate that 
publication bias can be safely ignored. In both high versus low intake and dose–response meta-analysis, visual 
inspection of funnel plots suggested moderate small study effects towards the null for yogurt and risk of CHD, 
due to the right-skewed form of the funnel plots. We considered the two bibliographic databases PubMed and 
Embase to be the most important information sources to search studies. We did not supplement our search by 
consulting other experts in the field as unpublished studies may tend to be of lower quality and because only 
a biased sample of such studies can be  identified25. On the other hand, it can be argued that inclusion of only 
published studies may introduce publication  bias25. Furthermore, the lack of searching non-English databases 
may be a source of publication  bias61. We did not search grey literature (such as reports), because grey literature 
may not have been subject to peer review and therefore may be of lower quality. Searching study registries was 
not considered relevant. Until recently, specified food substitutions have not been addressed in cohort studies 
on dairy and CVDs. Thus, summarizing findings on substitutions between dairy products were possible from 
only two studies. The lack of specifying substitutions in most previous cohort studies has implications for the 
interpretation of the results of our systematic review and meta-analysis as the effect of a specific dairy product 
on CVD depends on the replaced  foods62.
Guo et al.9 summarized findings of cohort studies on the associations between total intake of milk (11 stud-
ies), total intake of yogurt (3 studies) and cheese (9 studies) and the risk of CHD and observed no associations 
in their systematic review from 2017. The meta-analysis on milk intake and CHD risk was subsequently updated 
with one study by Soedamah-Muthu & de  Goede63. In agreement with previous findings, no association between 
total intake of milk and CHD was observed. Also, we did not observe any association for total intake of milk or 
yogurt with CHD. But we observed an inverse association between intake of cheese and risk of CHD in agree-
ment with the findings by Chen et al.8 in their meta-analysis of eight prospective observational studies on cheese 
intake and CHD risk from 2017. The effect of cheese intake on blood lipids was reviewed and summarized in 2015 
by de Goede et al.64. The authors found that intake of hard cheese decreased total cholesterol, LDL-cholesterol 
Figure 4.  Linear dose–response meta-analysis. Summary RR of CHD (panel a) and ischemic stroke (panel b) 




Scientific Reports |         (2021) 11:1303  | https://doi.org/10.1038/s41598-020-79708-x
www.nature.com/scientificreports/
and high-density lipoprotein (HDL)-cholesterol when compared with intake of butter of a similar ratio of poly-
unsaturated fatty acids to saturated fatty acids, and speculated that calcium, specific types of saturated fatty 
acids or the food matrix may explain the findings. However, in a cohort study (published after we finished our 
literature search), no association between substitution of cheese for butter was  observed65. In line with the meta-
analysis of three prospective observational studies on butter intake and CHD risk from 2016 by Pimpin et al.7, 
we observed no association between butter intake and CHD risk. Associations for low- and high-fat milk intake 
with major atherosclerotic CVDs have not been considered in previous systematic reviews. We observed that 
higher intake of high-fat milk was associated with higher risk of CHD. For intake of low-fat milk, no association 
was observed. High-fat milk has a high saturated fat content that may partly explain the findings of a higher risk 
Figure 5.  Linear dose–response meta-analysis. Summary RR of ischemic stroke for substitutions between dairy 
product subgroups (per 1 serving/day). For example in the mean of substitution of low-fat milk for high-fat 
milk; i.e. low-fat milk takes the place of high-fat milk). For milk and yogurt, the serving size was 200 g, for 
cheese 20 g, and for butter 6 g. Yogurt defined as yogurt/other soured milk products. CI confidence interval; M 
males; RR risk ratio; W women.
24
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of CHD associated with a higher intake of high-fat milk. Results from dietary trials have shown that whole-fat 
milk increases total cholesterol and LDL-cholesterol more than low-fat milk such as skim  milk66. However, the 
effects of whole-fat milk on HDL-cholesterol and the ratio of total cholesterol to HDL-cholesterol were less  clear66.
de Goede et al.6 summarized findings of cohort studies on the association between intake of dairy products 
and risk of ischemic and hemorrhagic stroke aggregated in their systematic review from 2016. In subgroup 
Table 3.  Linear dose–response meta-analysis on dairy product subgroups and risk of coronary heart disease, 
and NutriGrade meta-evidence grading. CI confidence interval; RR risk ratio. a Yogurt defined as yogurt/
other soured milk products. b Scoring for effects size was based on summary RR estimates from dose–response 
meta-analysis. c P = 0.12. d There is low confidence in the effect estimate; further research will provide important 
evidence on the confidence and likely change the effect estimate. e P = 0.04. f There is moderate confidence in the 
effect estimate, further research could add evidence on the confidence and may change the effect estimate.
Dairy  producta Amount Number of studies Summary  RRb 95% CI I2 (%) NutriGrade grading grading
Milk Per 200 g 5 1.02 1.00, 1.04c 0 Lowd
Low-fat milk Per 200 g 3 1.05 0.96, 1.13 24 Low
High-fat milk Per 200 g 4 1.08 1.00, 1.16e 0 Moderatef
Yogurt Per 100 g 5 0.98 0.93, 1.03 42 Low
Low-fat yogurt – – – – – –
High-fat yogurt – – – – – –
Cheese Per 20 g 6 0.96 0.93, 0.98 3 Moderate
Low-fat cheese Per 20 g 2 1.24 0.76, 2.04 90 Low
High-fat cheese – – – – – –
Butter Per 6 g 3 1.00 0.99, 1.01 0 Low
Table 4.  Linear dose–response meta-analysis on dairy product subgroups and risk of ischemic stroke, and 
NutriGrade meta-evidence grading. CI confidence interval; RR risk ratio. a Yogurt defined as yogurt/other 
soured milk products. b Scoring for effects size was based on summary RR estimates from dose–response meta-
analysis. c There is low confidence in the effect estimate, further research will provide important evidence on 
the confidence and likely change the effect estimate. d Substitutions between dairy product subgroups (per 1 
serving/day). For example in the mean of substitution of low-fat milk for high-fat milk; i.e. low-fat milk takes 
the place of high-fat milk. For milk and yogurt, the serving size was 200 g, for cheese 20 g, and for butter 6 g. 
e There is very low confidence in the effect estimate; meta-evidence is very limited and uncertain.
Dairy  producta Amount Number of studies Summary  RRb 95% CI I2 (%) NutriGrade grading
Milk Per 200 g 3 0.96 0.91, 1.01 16 Lowc
Low-fat milk – – – – – –
High-fat milk – – – – – –
Yogurt Per 100 g 2 0.99 0.90, 1.10 12 Low
Low-fat yogurt – – – – – –
High-fat yogurt – – – – – –
Cheese Per 20 g 3 0.96 0.91, 1.01 67 Low
Low-fat cheese – – – – – –
High-fat cheese – – – – – –
Butter Per 6 g 2 1.00 0.99, 1.01 0 Low
Low-fat milk for high-fat  milkd Per 1 serving/day 2 0.98 0.91, 1.05 0 Very  lowe
Low-fat yogurt for high-fat 
yogurt Per 1 serving/day 2 1.57 0.77, 3.21 67 Very low
Low-fat yogurt for low-fat milk Per 1 serving/day 2 0.98 0.86, 1.12 7 Very low
Low-fat yogurt for high-fat milk Per 1 serving/day 2 0.97 0.85, 1.11 0 Very low
High-fat yogurt for low-fat milk Per 1 serving/day 2 0.59 0.24, 1.42 79 Very low
High-fat yogurt for high-fat milk Per 1 serving/day 2 0.58 0.24, 1.42 79 Very low
Cheese for low-fat milk Per 1 serving/day 2 0.97 0.92, 1.02 0 Very low
Cheese for high-fat milk Per 1 serving/day 2 0.95 0.88, 1.02 0 Very low
Cheese for low-fat yogurt Per 1 serving/day 2 0.98 0.97, 1.11 0 Very low
Cheese for high-fat yogurt Per 1 serving/day 2 1.66 0.68, 4.02 80 Very low
Cheese for butter Per 1 serving/day 2 0.98 0.94, 1.02 0 Very low
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analyses by stroke type (ischemic and hemorrhagic), associations with total intake of milk were investigated. 
No association between total intake of milk and risk of ischemic stroke (5 studies) was observed, but the 95% CI 
was compatible with meaningful benefits in line with our findings. In addition, no association between yogurt, 
cheese or butter and ischemic stroke was observed in our meta-analysis.
In conclusion, this systematic review and meta-analysis of cohort studies indicates a positive association 
between high-fat milk and the risk of CHD, with heterogeneity present in high versus low intake meta-analysis 
but not in linear dose–response meta-analysis. The observed heterogeneity in high versus low intake meta-
analysis could not be explained by pre-specified subgroup analyses. In addition, this systematic review and 
meta-analysis of cohort studies indicates an inverse association between intake of cheese and the risk of CHD, 
with heterogeneity present in high versus low intake meta-analysis but not in linear dose–response meta-analysis. 
The observed heterogeneity in high versus low intake meta-analysis could partly be explained by gender. The 
NutriGrade meta-evidence grading was rated moderate for the associations between high-fat milk and cheese 
and the risk of CHD. For all other associations between dairy product subgroups and risk of CHD or risk of 
ischemic stroke, the meta-evidence grading was rated low or very low. No studies on peripheral artery disease 
were identified. Studies with more details about types of dairy products, including fat content, are warranted. 
Furthermore, future studies should investigate substitutions between dairy product subgroups. Findings from 
dairy food substitution analyses are important in deriving food-based dietary guidelines. Finally, future studies 
should describe their methods and data in as much detail as feasible, to facilitate later systematic reviews and 
meta-analyses.
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